PE20211644A1 - Compuestos para tratar ciertas leucemias - Google Patents

Compuestos para tratar ciertas leucemias

Info

Publication number
PE20211644A1
PE20211644A1 PE2021000343A PE2021000343A PE20211644A1 PE 20211644 A1 PE20211644 A1 PE 20211644A1 PE 2021000343 A PE2021000343 A PE 2021000343A PE 2021000343 A PE2021000343 A PE 2021000343A PE 20211644 A1 PE20211644 A1 PE 20211644A1
Authority
PE
Peru
Prior art keywords
alkyl
leukemia
protein
compounds
abl1
Prior art date
Application number
PE2021000343A
Other languages
English (en)
Inventor
F Anthony Romero
Thorsten A Kirschberg
Randall Halcomb
Yiingzi Xu
Original Assignee
Terns Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Inc filed Critical Terns Inc
Publication of PE20211644A1 publication Critical patent/PE20211644A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta referido a un compuesto de la formula (I) o (Ia), en donde: R1 es arilo, heteroarilo, entre otras opciones; R2 es H, alquilo, cicloalquilo, heterocicloalquilo, entre otras opciones; R3 es H, alquilo, alquenilo, alquinilo, cicloalquilo, entre otros; R4 es alquilo, alquenilo o alquinilo; L es -NH-CO-, -CO-NH-, -NH-SO2-, o -SO2-NH-; X es O, S; Y es CH, C-(alquilo C1-C2), C-halo o N; Z es CR5 o N. Estos compuestos inhiben la actividad enzimatica de tirosina quinasa de una proteina seleccionada de la proteina Abelson (ABL1), proteina relacionada con Abelson (ABL2), o una proteina quimerica BCR-ABL1, por lo que se les emplea en el tratamiento de la leucemia, principalmente la leucemia mieloide cronica (CML), leucemia mieloide aguda (AML), o leucemia linfoblastica aguda (ALL).
PE2021000343A 2018-09-18 2019-09-17 Compuestos para tratar ciertas leucemias PE20211644A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862733029P 2018-09-18 2018-09-18
US201962816637P 2019-03-11 2019-03-11
US201962889929P 2019-08-21 2019-08-21
PCT/US2019/051567 WO2020061086A2 (en) 2018-09-18 2019-09-17 Compounds for treating certain leukemias

Publications (1)

Publication Number Publication Date
PE20211644A1 true PE20211644A1 (es) 2021-08-24

Family

ID=69774840

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000343A PE20211644A1 (es) 2018-09-18 2019-09-17 Compuestos para tratar ciertas leucemias

Country Status (17)

Country Link
US (2) US10889571B2 (es)
EP (1) EP3852745A4 (es)
JP (1) JP2022501429A (es)
KR (1) KR20210061377A (es)
CN (3) CN112770745B (es)
AU (1) AU2019342102A1 (es)
BR (1) BR112021004051A2 (es)
CA (1) CA3110576A1 (es)
CL (1) CL2021000637A1 (es)
CO (1) CO2021004704A2 (es)
IL (1) IL281427A (es)
MA (1) MA53664A (es)
MX (2) MX2021003093A (es)
PE (1) PE20211644A1 (es)
SG (1) SG11202102367TA (es)
TW (1) TWI826525B (es)
WO (1) WO2020061086A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019353144B2 (en) 2018-10-05 2023-11-16 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
TW202118756A (zh) * 2019-07-29 2021-05-16 大陸商蘇州亞盛藥業有限公司 作為ｂｃｒ－ａｂｌ抑制劑的雜環化合物
JP2024510935A (ja) * 2021-03-03 2024-03-12 ターンズ・ファーマシューティカルズ・インコーポレイテッド 甲状腺ホルモン受容体ベータアゴニスト化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2241285T3 (es) * 1998-05-22 2005-10-16 Avanir Pharmaceuticals Derivados bencimidazol como moduladores de ige.
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
PE20061378A1 (es) * 2005-04-20 2006-12-03 Smithkline Beecham Corp INHIBIDORES DE LA ACTIVIDAD DE Akt
AR063311A1 (es) * 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
CN101553468A (zh) * 2006-10-18 2009-10-07 诺瓦提斯公司 有机化合物
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2018191146A1 (en) * 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof

Also Published As

Publication number Publication date
US10889571B2 (en) 2021-01-12
TWI826525B (zh) 2023-12-21
KR20210061377A (ko) 2021-05-27
CL2021000637A1 (es) 2021-10-01
CA3110576A1 (en) 2020-03-26
EP3852745A2 (en) 2021-07-28
BR112021004051A2 (pt) 2021-05-25
WO2020061086A3 (en) 2020-07-23
CO2021004704A2 (es) 2021-04-30
MX2023007714A (es) 2023-07-10
TW202024037A (zh) 2020-07-01
CN112770745A (zh) 2021-05-07
AU2019342102A1 (en) 2021-03-11
CN115215838A (zh) 2022-10-21
MX2021003093A (es) 2021-05-12
WO2020061086A2 (en) 2020-03-26
US20200087283A1 (en) 2020-03-19
CN115448908A (zh) 2022-12-09
SG11202102367TA (en) 2021-04-29
EP3852745A4 (en) 2022-05-04
MA53664A (fr) 2022-05-04
CN112770745B (zh) 2022-09-02
IL281427A (en) 2021-04-29
US20240101536A1 (en) 2024-03-28
JP2022501429A (ja) 2022-01-06

Similar Documents

Publication Publication Date Title
PE20211644A1 (es) Compuestos para tratar ciertas leucemias
PE20210004A1 (es) Inhibidores de mcl-1
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
PE20181803A1 (es) Inhibidores de mcl-1 macrociclicos para tratar el cancer
MD3810602T2 (ro) Compuşi
PE20220141A1 (es) Inhibidores de la proteina tirosina fosfatasa
CR20160127A (es) Pesticidas de azoles bicíclicos sustituidos con heterociclos
ATE446752T1 (de) Hemmer der akt aktivität
ATE512957T1 (de) Hemmer der akt aktivität
EA201992322A2 (ru) Соединения и композиции для лечения гематологических расстройств
CL2016002033A1 (es) Compuestos derivados de benzimidazol-2 amino con actividad inhibidora (midh1 r132h); composición farmacéutica, procedimiento de preparación; uso en el tratamiento de tumores gastrointestinales, tumor endocrino, síndrome mielodisplásico, leucemia, tumor de mamas, , metástasis, entre otros.
PE20200292A1 (es) Compuestos de heteroarilo biciclicos 6-6 fusionados y su uso como inhibidores de lats
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
ECSP056072A (es) Pirimidinonas sustituidas
UA107804C2 (en) Mixtures of pesticides mezoionnyh
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
UY31750A (es) Compuestos y composiciones como inhibidores de quinasa
MX2016008910A (es) Compuestos de fenil-triazolo-piridina.
EA201892815A1 (ru) Новые антибактериальные соединения
MD20230027A2 (ro) Amestecuri de pesticide cu conţinut de indazoli
PE20220281A1 (es) Compuestos de aza-benzotiofeno y aza-benzofurano como antihelminticos
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака